Here, we report that the combination of type-I interferon therapy (IFN) with 5’-Aza-2’-deoxycitidine (Aza) profoundly enhanced the therapeutic anti- melanoma efficacy of a MIP-3α-Gp100-Trp2 DNA vaccine. This evidence concerns the gene CCL20 and melanoma.